Home
VXRT
VXRT News

Latest Vaxart Inc (VXRT) News on June 1, 2025

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

GlobeNewswire

3 days ago

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders

GlobeNewswire

3 days ago

Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

GlobeNewswire

4 days ago

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

GlobeNewswire

5 days ago

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart Announces Adjournment of Annual Meeting of Stockholders

GlobeNewswire

11 days ago

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

12 days ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

GlobeNewswire

16 days ago

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

GlobeNewswire

17 days ago

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

GlobeNewswire

18 days ago

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

Vaxart Inc (VXRT) Q1 2025 Earnings Call Highlights: Strategic Progress Amidst Challenges

GuruFocus.com

18 days ago

Vaxart Inc (VXRT) Q1 2025 Earnings Call Highlights: Strategic Progress Amidst Challenges

MT Newswires

19 days ago

Vaxart Q1 Net Loss Narrows, Revenue Rises; Jeroen Grasman Named CFO

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

GlobeNewswire

19 days ago

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

GlobeNewswire

19 days ago

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

GlobeNewswire

20 days ago

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

GlobeNewswire

a month ago

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

GlobeNewswire

a month ago

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Vaxart to Present at the Citizens Life Sciences Conference

GlobeNewswire

a month ago

Vaxart to Present at the Citizens Life Sciences Conference

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

GlobeNewswire

a month ago

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

GlobeNewswire

2 months ago

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

GlobeNewswire

2 months ago

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

2 months ago

Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Vaxart Inc Earnings Call

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ...

GuruFocus.com

2 months ago

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ...

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

Zacks

2 months ago

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

GlobeNewswire

2 months ago

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

GlobeNewswire

3 months ago

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

GlobeNewswire

3 months ago

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

GlobeNewswire

3 months ago

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

GlobeNewswire

4 months ago

Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

GlobeNewswire

5 months ago

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

MT Newswires

5 months ago

Vaxart Says Oral Covid-19 Vaccine Candidate Recommended for Continued Study

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

GlobeNewswire

5 months ago

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Vaxart project agreement change ups funding for oral COVID vaccine candidate

TipRanks

5 months ago

Vaxart project agreement change ups funding for oral COVID vaccine candidate

MT Newswires

5 months ago

Top Midday Gainers

MT Newswires

5 months ago

Vaxart Gets Increased Funding for COVID-19 Pill Vaccine Study

MT Newswires

6 months ago

Vaxart Completes Sentinel Cohort Enrollment in Phase 2b COVID-19 Vaccine Trial

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

GlobeNewswire

6 months ago

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Vaxart Third Quarter 2024 Earnings: Beats Expectations

Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...

GuruFocus.com

7 months ago

Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ...

VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates

Zacks

7 months ago

VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire

7 months ago

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

GlobeNewswire

7 months ago

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gain

Simply Wall St.

7 months ago

Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gain

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

GlobeNewswire

7 months ago

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

GlobeNewswire

8 months ago

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances

GuruFocus.com

8 months ago

Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

GlobeNewswire

8 months ago

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

9 months ago

Vaxart Says Preclinical Data Support Potential Vaccine Against HPV-Related Cervical Dysplasia

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

GlobeNewswire

9 months ago

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Benzinga

10 months ago

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Vaxart Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

10 months ago

Vaxart Second Quarter 2024 Earnings: Misses Expectations

Thomson Reuters StreetEvents

10 months ago

Q2 2024 Vaxart Inc Earnings Call

VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates

Zacks

10 months ago

VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire

10 months ago

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

GlobeNewswire

10 months ago

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

While institutions invested in Vaxart, Inc. (NASDAQ:VXRT) benefited from last week's 23% gain, retail investors stood to gain the most

Simply Wall St.

a year ago

While institutions invested in Vaxart, Inc. (NASDAQ:VXRT) benefited from last week's 23% gain, retail investors stood to gain the most

Vaxart Provides Business Update

GlobeNewswire

a year ago

Vaxart Provides Business Update

Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering

Benzinga

a year ago

Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering

MT Newswires

a year ago

Vaxart Receives $453 Million for Phase 2b Trial of Covid-19 Oral Pill Vaccine Candidate

MT Newswires

a year ago

Vaxart Launches $40 Million Share Offering; Shares Rise Pre-Bell

Vaxart Announces $40 Million Underwritten Offering of Common Stock

GlobeNewswire

a year ago

Vaxart Announces $40 Million Underwritten Offering of Common Stock

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

GlobeNewswire

a year ago

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thomson Reuters StreetEvents

a year ago

Q1 2024 Vaxart Inc Earnings Call

GuruFocus.com

a year ago

Vaxart Inc (VXRT) Q1 2024 Earnings Call Transcript Highlights: Promising Developments and ...

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

GlobeNewswire

a year ago

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

GlobeNewswire

a year ago

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

GlobeNewswire

a year ago

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)

Simply Wall St.

a year ago

Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q4 2023 Vaxart Inc Earnings Call

Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results

GuruFocus.com

a year ago

Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

GlobeNewswire

a year ago

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

GlobeNewswire

a year ago

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

GlobeNewswire

a year ago

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?

Zacks

a year ago

VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?

VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?

Zacks

a year ago

VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

GlobeNewswire

a year ago

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

Strong week for Vaxart (NASDAQ:VXRT) shareholders doesn't alleviate pain of three-year loss

Simply Wall St.

a year ago

Strong week for Vaxart (NASDAQ:VXRT) shareholders doesn't alleviate pain of three-year loss

Zoomcar Introduces New Product Category with 50% Lower Pricing

GlobeNewswire

a year ago

Zoomcar Introduces New Product Category with 50% Lower Pricing

Financial Institutions, Inc. (NASDAQ:FISI) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Financial Institutions, Inc. (NASDAQ:FISI) Q4 2023 Earnings Call Transcript

Investar Holding Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a year ago

Investar Holding Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

BRAEMAR HOTELS & RESORTS ANNOUNCES TAX REPORTING INFORMATION FOR 2023 COMMON AND PREFERRED SHARE DISTRIBUTIONS

PR Newswire

a year ago

BRAEMAR HOTELS & RESORTS ANNOUNCES TAX REPORTING INFORMATION FOR 2023 COMMON AND PREFERRED SHARE DISTRIBUTIONS

Domo (DOMO) Soars 9.0%: Is Further Upside Left in the Stock?

Zacks

a year ago

Domo (DOMO) Soars 9.0%: Is Further Upside Left in the Stock?

Universal Stainless & Alloy Products, Inc. (NASDAQ:USAP) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Universal Stainless & Alloy Products, Inc. (NASDAQ:USAP) Q4 2023 Earnings Call Transcript

Associated Press Finance

a year ago

LSI: Fiscal Q2 Earnings Snapshot

LSI Industries Reports Fiscal 2024 Second Quarter Results and Declares Quarterly Cash Dividend

Business Wire

a year ago

LSI Industries Reports Fiscal 2024 Second Quarter Results and Declares Quarterly Cash Dividend

Brookline Bancorp Inc (BRKL) Reports Mixed Fourth Quarter Results Amidst Industry Headwinds

GuruFocus.com

a year ago

Brookline Bancorp Inc (BRKL) Reports Mixed Fourth Quarter Results Amidst Industry Headwinds

Institutions profited after Omeros Corporation's (NASDAQ:OMER) market cap rose US$23m last week but individual investors profited the most

Simply Wall St.

a year ago

Institutions profited after Omeros Corporation's (NASDAQ:OMER) market cap rose US$23m last week but individual investors profited the most

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

GlobeNewswire

a year ago

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

GlobeNewswire

a year ago

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

Vaxart, Inc. Announces Management Change

GlobeNewswire

a year ago

Vaxart, Inc. Announces Management Change

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

GlobeNewswire

a year ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

At US$6.89, Is Immersion Corporation (NASDAQ:IMMR) Worth Looking At Closely?

Simply Wall St.

a year ago

At US$6.89, Is Immersion Corporation (NASDAQ:IMMR) Worth Looking At Closely?

GlobeNewswire

a year ago

Zoomcar, the World’s Largest Emerging Market Focused Car Sharing Platform, Announces Completion of its Business Combination with Innovative International Acquisition Corporation (IOAC) and Anticipated Nasdaq Listing

Share on Social Networks: